Plasma MCP-1 and changes on cognitive function in community-dwelling older adults
| العنوان: | Plasma MCP-1 and changes on cognitive function in community-dwelling older adults |
|---|---|
| المؤلفون: | Juan Luis Sanchez-Sanchez, Kelly V. Giudici, Sophie Guyonnet, Julien Delrieu, Yan Li, Randall J. Bateman, Angelo Parini, Bruno Vellas, Philipe de Souto Barreto, for the MAPT/DSA Group |
| المصدر: | Alzheimer’s Research & Therapy, Vol 14, Iss 1, Pp 1-13 (2022) ABACUS. Repositorio de Producción Científica Universidad Europea (UEM) Alzheimer's Research & Therapy |
| بيانات النشر: | BMC, 2022. |
| سنة النشر: | 2022 |
| مصطلحات موضوعية: | Male, Bioquímica, Cognitive Neuroscience, Enfermedad del sistema nervioso, Neurosciences. Biological psychiatry. Neuropsychiatry, Neuropsychological Tests, Plasma, Cognition, Medicina preventiva, Alzheimer Disease, Enfermedad de Alzheimer, Humans, Cognitive Dysfunction, RC346-429, Chemokine CCL2, Quimiocina CCL2, Aged, Amyloid beta-Peptides, Episodic memory, Research, Neurology, Older adults, Female, Independent Living, Neurology (clinical), Cognitive function, Neurology. Diseases of the nervous system, Alzheimer’s disease, MCP-1, RC321-571 |
| الوصف: | BackgroundMonocyte Chemoattractant Protein-1 (MCP-1), a glial-derived chemokine, mediates neuroinflammation and may regulate memory outcomes among older adults. We aimed to explore the associations of plasma MCP-1 levels (alone and in combination with β-amyloid deposition—Aβ42/40) with overall and domain-specific cognitive evolution among older adults.MethodsSecondary analyses including 1097 subjects (mean age = 75.3 years ± 4.4; 63.8% women) from the Multidomain Alzheimer Preventive Trial (MAPT). MCP-1 (higher is worse) and Aβ42/40(lower is worse) were measured in plasma collected at year 1. MCP-1 in continuous and as a dichotomy (values in the highest quartile (MCP-1+)) were used, as well as a dichotomy of Aβ42/40. Outcomes were measured annually over 4 years and included the following: cognitive compositez-score (CCS), the Mini-Mental State Examination (MMSE), and Clinical Dementia Rating (CDR) sum of boxes (overall cognitive function); composite executive functionz-score, composite attentionz-score, Free and Cued Selective Reminding Test (FCSRT - memory).ResultsPlasma MCP-1 as a continuous variable was associated with the worsening of episodic memory over 4 years of follow-up, specifically in measures of free and cued delayed recall. MCP-1+was associated with worse evolution in the CCS (4-year between-group difference:β= −0.14, 95%CI = −0.26, −0.02) and the CDR sum of boxes (2-year:β= 0.19, 95%CI = 0.06, 0.32). In domain-specific analyses, MCP-1+was associated with declines in the FCSRT delayed recall sub-domains. In the presence of low Aβ42/40, MCP-1+was not associated with greater declines in cognitive functions. The interaction with continuous biomarker valuesAβ42/40× MCP-1 × timewas significant in models with CDR sum of boxes and FCSRT DTR as dependent variables.ConclusionsBaseline plasma MCP-1 levels were associated with longitudinal declines in overall cognitive and episodic memory performance in older adults over a 4-year follow-up. How plasma MCP-1 interacts with Aβ42/40to determine cognitive decline at different stages of cognitive decline/dementia should be clarified by further research. The MCP-1 association on cognitive decline was strongest in those with amyloid plaques, as measured by blood plasmaAβ42/40. |
| اللغة: | English |
| تدمد: | 1758-9193 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fae01ca22ea12ec628f4576ec99c52afTest https://doaj.org/article/1cfb3343946a4f849944b70f0209cf92Test |
| حقوق: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....fae01ca22ea12ec628f4576ec99c52af |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 17589193 |
|---|